K. Kato Et Al. , "A phase 3 study of chemotherapy 1 pembrolizumab versus chemotherapy 1 placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590-Trial in progress," ESMO 20th World Congress on Gastrointestinal Cancer , vol.29, Barcelona, Spain, 2018
Kato, K. Et Al. 2018. A phase 3 study of chemotherapy 1 pembrolizumab versus chemotherapy 1 placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590-Trial in progress. ESMO 20th World Congress on Gastrointestinal Cancer , (Barcelona, Spain).
Kato, K., Shah, M., Enzinger, P., Bennouna, J., Shen, L., Adenis, A., ... Sun, J.(2018). A phase 3 study of chemotherapy 1 pembrolizumab versus chemotherapy 1 placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590-Trial in progress . ESMO 20th World Congress on Gastrointestinal Cancer, Barcelona, Spain
Kato, K. Et Al. "A phase 3 study of chemotherapy 1 pembrolizumab versus chemotherapy 1 placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590-Trial in progress," ESMO 20th World Congress on Gastrointestinal Cancer, Barcelona, Spain, 2018
Kato, K. Et Al. "A phase 3 study of chemotherapy 1 pembrolizumab versus chemotherapy 1 placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590-Trial in progress." ESMO 20th World Congress on Gastrointestinal Cancer , Barcelona, Spain, 2018
Kato, K. Et Al. (2018) . "A phase 3 study of chemotherapy 1 pembrolizumab versus chemotherapy 1 placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590-Trial in progress." ESMO 20th World Congress on Gastrointestinal Cancer , Barcelona, Spain.
@conferencepaper{conferencepaper, author={K. Kato Et Al. }, title={A phase 3 study of chemotherapy 1 pembrolizumab versus chemotherapy 1 placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590-Trial in progress}, congress name={ESMO 20th World Congress on Gastrointestinal Cancer}, city={Barcelona}, country={Spain}, year={2018}}